The clinical efficacy and safety of kanglaite adjuvant therapy in the treatment of advanced hepatocellular carcinoma: a PRISMA-compliant meta-analysis.

The clinical efficacy and safety of kanglaite adjuvant therapy in the treatment of advanced hepatocellular carcinoma: a PRISMA-compliant meta-analysis. Biosci Rep. 2019 Nov 12;: Authors: Liu J, Liu X, Ma J, Li K, Xu C Abstract Kanglaite, a type of Chinese medicine preparation, is considered a promising complementary therapy option for advanced hepatocellular carcinoma (HCC). Although an analysis of the published literature has been performed, the exact effects and safety have yet to be systematically investigated. Therefore, we conducted a wide-ranging online search of electronic databases to provide systematic conclusions; data from 31 trials with 2,315 HCC patients were included. The results indicated that compared with conventional treatment (CT) alone, the combination of kanglaite with CT markedly prolonged patients' 6-month overall survival (OS, P = 0.003), 12-month OS (P < 0.0001), 18-month OS (P = 0.003), 24-month OS (P = 0.03) and 36-month OS (P = 0.0006) and significantly improved the overall response rate (OR = 2.57, 95% CI = 2.10-3.16, P < 0.00001) and disease control rate (OR = 3.10, 95% CI = 2.42-3.97, P < 0.00001) of patients. The quality of life, clinical symptoms and immune function of patients were also obviously improved after combined treatment. The incidence rates of nausea and vomiting (P = 0.04), hepatotoxicity (P = 0.0002), leukopenia (P < 0.00001), thrombocytopenia (P &...
Source: Bioscience Reports - Category: Biomedical Science Authors: Tags: Biosci Rep Source Type: research